FOXO4-DRI · Research brief
FOXO4-DRI Peptide: Research, Purity Data and Sourcing
Short answer
Clearing senescent cells is not automatically beneficial. A 2023 Circulation paper titled Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression reported the opposite of what most senolytic marketing implies, and it sits in the same body of literature as the 2017 Cell study that introduced FOXO4-DRI to the field. Both findings are real. Both matter.
Key takeaways
- FOXO4-DRI is a D-retro-inverso peptide built from reversed-sequence D-amino acids, a format chosen specifically because mammalian proteases recognise that backbone poorly.
- The published mechanism is competitive disruption of the FOXO4 and p53 interface, which drives p53 out of the nucleus and allows apoptosis to proceed in senescent cells.
- The 2017 Cell paper on targeted apoptosis of senescent cells is the foundational FOXO4-DRI study, with a 2023 pulmonary fibrosis model and a 2025 keloid fibroblast study as the main follow-ups.
- A 2023 Circulation paper found that eliminating senescent cells can worsen pulmonary hypertension, which establishes that senolytic clearance is context-dependent rather than universally beneficial.
- No standardised half-life or human pharmacokinetic profile for FOXO4-DRI has been published, and any confident figure should be traced to a specific citation before it is believed.
- Verification requires three documents together: a batch-matched certificate of analysis, an HPLC chromatogram with stated method conditions, and a mass spectrometry trace confirming identity.
Clearing senescent cells is not automatically beneficial. A 2023 Circulation paper titled Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression reported the opposite of what most senolytic marketing implies, and it sits in the same body of literature as the 2017 Cell study that introduced FOXO4-DRI to the field. Both findings are real. Both matter.
That tension is the most useful thing to grasp before reading anything else about FOXO4-DRI. Our team tracks this literature continuously because laboratory buyers ask us the same three questions every week: what the molecule is at the chemistry level, what the published evidence actually supports, and how to confirm a vial matches its label. Every study claim below carries a PubMed link.
'What is FOXO4-DRI?'
FOXO4-DRI is a synthetic D-retro-inverso peptide modelled on a segment of the FOXO4 transcription factor. In published cell and animal research it behaves as a senolytic candidate, disrupting the FOXO4 interaction with p53 inside senescent cells and promoting their apoptosis. It is a research-use-only compound with no approved medical indication anywhere in the world.
The common oversimplification is that FOXO4-DRI simply kills so-called zombie cells. The published mechanism is narrower and more interesting: the peptide competes for a specific protein-protein interface, and the apoptotic outcome depends entirely on whether a given cell type relies on that interface to keep p53 restrained. This page covers the chemistry, the mechanism, the full published evidence base, the reported unknowns around safety and pharmacokinetics, and the analytical paperwork that separates a verified vial from an unverified one.
What is FOXO4-DRI, exactly?
FOXO4-DRI is a short peptide derived from a stretch of the FOXO4 forkhead domain, synthesised as a D-retro-inverso construct. That term describes a specific chemical trick: the amino acid sequence is reversed and every residue is built from the D-enantiomer rather than the naturally occurring L-form. The result is a molecule whose side-chain topology closely mimics the parent L-peptide while presenting a backbone that mammalian proteases struggle to recognise.
The construct also carries a cell-penetrating segment, which is why FOXO4-DRI appears in intracellular protein-interaction studies rather than being confined to surface receptor work. Suppliers and papers use several names for the same material: FOXO4-DRI, FOXO4-D-Retro-Inverso, and the alias Proxofim. The 2023 fibrosis paper FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts uses the full spelled-out form, which is worth knowing when searching databases.
One detail that catches new researchers out: FOXO4-DRI is not a FOXO4 inhibitor in the conventional small-molecule sense. It does not block the transcription factor's DNA-binding activity across the board. It interferes with one interaction partner. The distinction changes how a control arm should be designed, and we see it misunderstood in roughly half the enquiries we field about cellular senescence research.
How does the peptide interfere with the FOXO4 and p53 interface?
FOXO proteins are a family of forkhead box transcription factors that act as integration points for stress, nutrient and growth signalling. The review Introduction to FOXO Biology and the 2022 FEBS J piece FOXOs: masters of the equilibrium both frame the family as homeostatic regulators rather than simple on-off switches, and the 2024 Nature Reviews Molecular Cell Biology article FOXO transcription factors as mediators of stress adaptation extends that framing to cellular stress responses broadly.
Here is the specific mechanism FOXO4-DRI exploits. In senescent cells, FOXO4 associates with p53 and holds it in the nucleus, a configuration that keeps p53 from initiating mitochondrial apoptosis. FOXO4-DRI competes for that binding interface. Displaced p53 relocates out of the nucleus, and the apoptotic programme that senescence had suppressed proceeds. The 2025 Communications Biology study FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation documents that nuclear-exclusion step directly, down to the phosphorylation state involved.
The structural basis has since been examined in its own right. The 2025 Nature Communications paper Structural plasticity of the FOXO-DBD:p53-TAD interaction characterises the interface between the FOXO DNA-binding domain and the p53 transactivation domain, which is precisely the contact a competitive peptide must out-compete. Reading that paper alongside the 2022 Trends in Pharmacological Sciences review FOXO transcription factors as therapeutic targets in human diseases gives a far clearer picture of why selectivity is the hard part of this entire approach.
What has the published research on this peptide actually shown?
The foundational study is the 2017 Cell paper Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. It introduced the FOXO4-DRI approach and reported that selectively triggering apoptosis in senescent cells restored tissue homeostasis in models of chemotoxicity and ageing. Nearly every subsequent FOXO4-DRI citation traces back to this work.
Two later papers extended the compound into specific disease models. The 2023 Naunyn-Schmiedeberg's Archives of Pharmacology study reported that FOXO4-D-Retro-Inverso targeted extracellular matrix production in fibroblasts and ameliorated bleomycin-induced pulmonary fibrosis in mice, which is notable because it points at a fibroblast-matrix axis rather than senescence alone. The 2025 keloid fibroblast paper then tied apoptosis in a human-derived fibrotic cell type back to the p53 nuclear-exclusion mechanism.
Surrounding that narrow FOXO4-DRI literature is a much larger FOXO biology literature that researchers should read before designing anything. FoxO3a and disease progression covers the disease associations of a closely related family member, FOXO Transcriptional Factors and Long-Term Living covers the longevity genetics angle, and the 2020 Nature Cell Biology paper FoxO maintains a genuine muscle stem-cell quiescent state until geriatric age shows FOXO signalling doing something essential and protective. Interfering with this family is not a one-directional intervention, which is the practical point most senolytic clearance summaries skip.
What side effects and unknowns does the literature report?
No peer-reviewed human safety dataset for FOXO4-DRI exists in the published literature. There are no registered clinical trial results, no characterised adverse-event profile, and no regulatory review of any kind. Any page claiming a known side effect profile for FOXO4-DRI in people is describing something that has not been published.
What the literature does supply is a serious mechanistic caution. The 2023 Circulation study found that eliminating senescent cells can promote pulmonary hypertension development and progression, which means senescent-cell clearance is context-dependent rather than uniformly restorative. Senescent cells participate in wound healing, tissue remodelling and tumour suppression, so a broadly effective clearance agent is also a broadly disruptive one.
The second unknown is selectivity. Because FOXO4-DRI acts on a protein-protein interface present in non-senescent cells as well, off-target apoptosis in healthy populations is a live design question in any experiment, not a solved problem. The third is species translation: the fibrosis data come from mice, the keloid data from a specific human fibroblast type, and neither generalises automatically. Our team's consistent position when researchers ask about the senolytic literature is that the unknowns outnumber the knowns, and honest study design starts from that admission.
What is known about its half-life and pharmacokinetics?
There is no standardised, widely replicated half-life value for FOXO4-DRI in the open literature, and we will not invent one. What is well established is the design rationale: D-retro-inverso peptides are built specifically to resist proteolytic degradation, because proteases that cleave L-amino acid backbones recognise the D-enantiomer backbone poorly. Extended stability relative to the equivalent L-peptide is the entire reason the retro-inverso format was chosen for FOXO4-DRI in the first place.
That design advantage is a chemical property, not a published pharmacokinetic parameter. Plasma half-life, area under the curve, tissue distribution and clearance route for FOXO4-DRI have not been characterised in the kind of systematic study that would let anyone quote a number with confidence. Researchers encountering a confident half-life figure on a supplier page should ask which paper it came from, because in our reading of the FOXO4-DRI literature, that citation usually does not exist.
For in vitro work, the more relevant stability question is solution stability rather than circulating half-life: how long reconstituted FOXO4-DRI retains integrity in a given buffer, at a given temperature, across a given number of freeze-thaw cycles. That is measurable in-house with analytical HPLC and is a far better use of effort than chasing an unpublished pharmacokinetic constant. Several of the refrigeration and handling questions we receive are really solution-stability questions in disguise.
How do researchers verify that a FOXO4-DRI vial is what the label says?
Three documents answer the question, and a vial without them is an unknown white powder. The first is the certificate of analysis, which should be batch-specific and name the exact lot printed on the vial, not a generic product-level PDF. The second is the HPLC chromatogram showing purity by peak area. The third is the mass spectrometry trace, typically ESI-MS or MALDI-TOF, confirming that the observed molecular mass matches the theoretical mass for the sequence.
Purity and identity are separate questions, and conflating them is the most common sourcing mistake we see. A high HPLC purity figure tells you the sample contains one dominant species. It does not tell you that the species is FOXO4-DRI. Only the mass spectrometry result establishes identity, and only the sequence on the COA establishes that the mass corresponds to the intended construct rather than a deletion variant or a truncation that happens to run clean.
Two further line items deserve attention on a FOXO4-DRI certificate. Net peptide content differs from gross vial weight because lyophilised material carries residual water and counter-ions such as acetate or trifluoroacetate, which means gravimetric weight overstates actual peptide. And the chromatogram should show the detection wavelength and the gradient conditions, because a purity figure without method conditions is not a reproducible measurement. Real Peptides supplies FOXO4-DRI for laboratory research with a published certificate of analysis for this reason. Researchers comparing vendors on documentation rather than claims usually start with third-party tested supplier criteria and COA-backed sourcing.
How should the material be handled and stored in a laboratory?
Standard laboratory practice for lyophilised research peptides applies to FOXO4-DRI without modification: keep the sealed vial frozen at around minus 20 degrees Celsius, protected from light and moisture, and allow it to equilibrate to room temperature before opening to prevent atmospheric condensation inside the vial. Hygroscopic uptake is the quiet failure mode here, because a peptide that has absorbed water looks identical to one that has not.
Once in solution, FOXO4-DRI is a different material with a different stability clock. Refrigerated storage at 2 to 8 degrees Celsius is standard for short working periods, and aliquoting into single-use volumes is the single most effective way to protect integrity, because repeated freeze-thaw cycling degrades peptides through aggregation and hydrolysis far faster than cold storage alone does.
Cold-chain integrity during transit matters just as much as bench storage. A lyophilised peptide tolerates brief ambient excursions better than a reconstituted one, but temperature history is cumulative and invisible. Our team's observation across hundreds of laboratory enquiries is that documentation and handling discipline, not the synthesis itself, is where research-grade FOXO4-DRI projects most often come apart. Supplier evaluation criteria and shipping and fulfilment practices belong in the same conversation as purity.
What is the legal and research-use-only status of this compound?
FOXO4-DRI is not an approved drug in any jurisdiction. It has not been evaluated by the FDA for safety or efficacy, it holds no approved indication, and it is not available as a prescription medicine. It exists in commerce as a laboratory reagent. All compounds discussed on this page are sold for research use only and are not for human consumption.
That classification carries practical obligations. Research-use-only material is supplied to qualified researchers and institutions for in vitro and laboratory work, is not manufactured to pharmaceutical finished-product standards, and must not be described, repackaged or resold as anything consumable. Nothing on this page is guidance for people or animals, and anyone with a question about an animal's health should talk to their veterinarian rather than extrapolating from a senolytic paper.
The gap between what FOXO4-DRI research shows and what online communities claim about it is wide, and it widens every year. We cover that gap directly in our overview of how biohacker communities discuss this compound and in our guidance on evaluating sellers responsibly.
How does it compare with other senolytic and longevity research compounds?
The table below compares FOXO4-DRI with three compounds that appear alongside it in senescence and longevity literature. Evidence levels are described qualitatively because the published bases differ in kind, not just in quantity.
| Compound | Molecule type | Primary molecular target | Published evidence base | Bottom line for researchers |
|---|---|---|---|---|
| FOXO4-DRI | D-retro-inverso peptide with cell-penetrating segment | FOXO4 and p53 protein-protein interface | Narrow but mechanistically detailed: one foundational 2017 Cell paper plus fibrosis and keloid fibroblast follow-ups | Strongest mechanistic story of the group, weakest breadth of replication. Best suited to targeted interface and apoptosis work, not broad screening |
| Epithalon | Short synthetic tetrapeptide | Reported telomerase and pineal-axis activity | Older and methodologically uneven literature, much of it difficult to access or independently replicate | Frequently compared with FOXO4-DRI but mechanistically unrelated. Treat published claims with more caution than the FOXO4 literature |
| Dasatinib plus quercetin | Small-molecule tyrosine kinase inhibitor combined with a plant flavonol | Senescent-cell anti-apoptotic pathways, acting broadly rather than on one interface | The most frequently referenced senolytic combination in the field, with an extensive preclinical literature | The practical benchmark comparator. Broader action means broader off-target exposure in any experimental design |
| Navitoclax (ABT-263) | Small-molecule BCL-2 family inhibitor from oncology | BCL-2 and BCL-xL anti-apoptotic proteins | Well characterised as an oncology agent, with documented haematological liabilities | Mechanistically potent and well studied, but its known toxicity profile makes it a reference point rather than a template |
Researchers specifically weighing peptide options against each other will find more detail in our side-by-side breakdown of Epithalon and FOXO4-DRI mechanisms and the shorter comparison overview.
What If: Common Laboratory Scenarios
What if the certificate of analysis lot number does not match the vial?
Quarantine the vial and request the correct batch document before any analytical or experimental work begins. A mismatched lot number means the purity and identity data in hand describe a different synthesis run, and peptide batches vary in impurity profile even from the same facility. Generic product-level certificates that carry no lot identifier provide no traceability at all, which is the entire reason batch-specific documentation exists.
What if the lyophilised powder looks different from a previous batch?
Document the appearance, photograph it, and verify identity analytically rather than visually. Lyophilised peptide cake appearance varies legitimately with freeze-drying conditions, fill volume and counter-ion content, so a fluffier or denser cake is not automatic evidence of a problem. Clumping or visible moisture, however, points to hygroscopic uptake during storage or transit, and that material should be assessed for water content before use.
What if a FOXO4-DRI experiment shows apoptosis in non-senescent control cells?
Treat that as a selectivity finding worth recording rather than a failed run. The FOXO4 and p53 interaction is not exclusive to senescent cells, and published FOXO biology, including the muscle stem-cell quiescence work, shows the family performing essential functions in healthy populations. Off-target apoptosis in controls is consistent with what the mechanism predicts and belongs in the results, not the bin.
The uncomfortable truth about senolytic peptide hype
Here is the honest answer: the gap between what FOXO4-DRI has shown in published research and what it is marketed as online is enormous, and almost none of that gap is scientific. One foundational Cell paper and two disease-model follow-ups is a thin evidence base by any standard, and the Circulation finding that senescent-cell removal can worsen disease should temper every sweeping claim made about this class. FOXO4-DRI is a genuinely interesting protein-interaction tool with a well-characterised mechanism and an almost entirely uncharacterised safety profile. Those two facts are not in conflict. They simply describe an early-stage research compound rather than a finished answer to anything.
How we researched this page
Every study claim on this page is drawn from peer-reviewed literature indexed on PubMed and linked inline so readers can check the source directly rather than take our summary on faith. We described each paper from its published title and scope, and where the literature does not supply a number, such as a replicated half-life value for FOXO4-DRI, we said so instead of estimating one.
We make no first-party testing claims here. Nothing on this page reports in-house experiments, internal assays or proprietary data on FOXO4-DRI. The analytical guidance in the verification section describes standard peptide quality-control methods, HPLC purity and mass spectrometry identity confirmation, as they are applied across the research-reagent industry generally.
Further reading in our research library
Researchers working through this compound in depth can continue with our overviews of anti-aging research questions, cellular renewal literature, senescent cell clearance work, and the zombie cell terminology researchers encounter. Sourcing and documentation topics are covered in general purchasing considerations, online ordering logistics, shipping within the United States, and peptide-specific purchasing questions. Frequently searched research questions are addressed in timing questions raised in the literature, frequency questions researchers ask, oral bioavailability of peptide constructs, the anti-aging evidence question, combination research discussions, clearance support claims examined, and the Epithalon combination literature.
FOXO4-DRI deserves better treatment than it usually gets, in both directions. The breathless version oversells one mouse study into a longevity solution, and the dismissive version ignores a genuinely elegant piece of protein engineering that turned a transcription factor interface into a selective apoptotic trigger. The compound sits exactly where early-stage research compounds sit: mechanistically compelling, thinly replicated, and far more useful as a question than as an answer. If a page about FOXO4-DRI is not showing you the certificate, the chromatogram and the citation, it is selling a story rather than a molecule.
References
Peer-reviewed sources on FOXO4-DRI indexed in PubMed, listed for research context. Real Peptides supplies FOXO4-DRI for laboratory research use only.
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg's archives of pharmacology, 2026. PMID 42024235. doi:10.1007/s00210-026-05309-6
- FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. Antioxidants (Basel, Switzerland), 2026. PMID 42510573. doi:10.3390/antiox15070842
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications biology, 2025. PMID 39994346. doi:10.1038/s42003-025-07738-0
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications, 2025. PMID 40593617. doi:10.1038/s41467-025-60844-9
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in bioengineering and biotechnology, 2025. PMID 41625068. doi:10.3389/fbioe.2025.1729166
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental gerontology, 2024. PMID 39025385. doi:10.1016/j.exger.2024.112522
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg's archives of pharmacology, 2023. PMID 37074394. doi:10.1007/s00210-023-02452-2
- FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of cellular and molecular medicine, 2022. PMID 35510614. doi:10.1111/jcmm.17333
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add vials.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA